Blog
News & Updates
Stay connected with the latest on adherence, real-world evidence, and product updates.
2025 Year-In-Review: The Era of the Connected Therapeutic
2025 marked a turning point in life sciences. Direct-to-patient strategies scaled, affordability pressures intensified, and federal programs like ACCESS and TEMPO accelerated the shift toward outcomes-driven care. This Year in Review examines how the “connected therapeutic” is redefining pharma brand strategy, patient trust, and the role of digital companions across the supply chain. We explore what changed for manufacturers, pharmacies, providers, and payers and why medication packages are becoming the new entry point for real-world engagement, evidence generation, and retention in 2026 and beyond.
The Missing Layer in Pharma’s DTP Strategy: Real-Time Adherence Intelligence
As direct-to-patient (DTP) models reshape how therapies reach patients, the true differentiator will no longer be access alone — it will be adherence. While programs like LillyDirect and PfizerForAll simplify the path to therapy, the next phase demands real-time engagement, context, and continuity. Synchronyx’s Tappt platform transforms each prescription into a digital companion that tracks adherence, captures real-world barriers, connects patients to timely care, and turns every refill into proof of value.